INTRODUCTION: Psoriasis ranges from mild to severe with the majority of patients having mild disease. Mild to moderate disease is often treated with topical therapies while photo-, oral, and biologic therapies are generally reserved for moderate-to-severe disease. There is a strong scientific rationale for the combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) with respect to mode of action, efficacy, and safety and CAL/BDP has shown an inhibitory effect on key pathogenic cytokines in psoriasis including tumor necrosis factor-α, interleukin (IL)-17, and IL-23. METHODS: The objective of this pooled post hoc analysis is to investigate the efficacy of CAL/BDP polyaphron dispersion (PAD)-cream in subgroups of patients with moderate-to-severe psoriasis from two completed phase 3 studies conducted in the USA and Europe. RESULTS: The proportion of patients achieving Physician Global Assessment (PGA) treatment success as well as a modified Psoriasis Area and Severity Index (mPASI)75 response was higher in the subgroup with a body surface area > 10% and mPASI > 10 and Dermatology Life Quality Index > 10 at baseline compared to the overall patient population. Furthermore, the numerical difference in treatment efficacy between CAL/BDP PAD-cream and CAL/BDP topical suspension/gel increased in patient subgroups with higher baseline severity. Similar patterns were shown for the patient-reported outcomes. CONCLUSION: In this subgroup analysis, patients who had higher disease severity at baseline achieved greater efficacy than the total patient population when treated with 8 weeks of CAL/BDP PAD-cream as compared to a currently marketed active comparator. Additionally, as indicated by this analysis, CAL/BDP PAD-cream treatment may also be more convenient and less greasy, which may reduce the burden of daily treatment and improve adherence to therapy. TRIAL REGISTRATION: NCT03308799 and NCT03802344.

Department of Dermatology Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Dermatology University Hospital Frankfurt am Main Frankfurt am Main Germany

Department of Dermatology University of Rzeszow Aleja Tadeusza Rejtana 16C Rzeszow Poland

Dermatology Clinical Research Henry Ford Health System Detroit MI USA

MC2 Therapeutics Hørsholm Denmark

Therapeutics Clinical Research San Diego CA USA

University Medical Center Hamburg Eppendorf Hamburg Germany

University of Southern California Los Angeles CA USA

Zobrazit více v PubMed

Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–224. doi: 10.1016/j.jaad.2008.09.022. PubMed DOI PMC

Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–J321. doi: 10.1016/j.jaut.2009.12.001. PubMed DOI

Schafer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006;212(4):327–337. doi: 10.1159/000092283. PubMed DOI

Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med. 2009;361(5):496–509. doi: 10.1056/NEJMra0804595. PubMed DOI

Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967. doi: 10.1016/j.jaad.2015.02.1099. PubMed DOI

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x. PubMed DOI

Psoriasis Statistics: National Psoriasis Foundation. https://www.psoriasis.org/psoriasis-statistics/. Accessed 31 May 2023

Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867. doi: 10.1111/j.1365-2133.2005.06502.x. PubMed DOI

Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi: 10.1111/j.0022-202X.2005.23621.x. PubMed DOI

Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi: 10.1016/j.jaci.2017.07.004. PubMed DOI PMC

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6. PubMed DOI

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057. PubMed DOI

Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470. doi: 10.1016/j.jaad.2020.07.087. PubMed DOI

Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185. doi: 10.1001/jamadermatol.2013.5264. PubMed DOI

Hoegsberg T, Iversen L, Lange MM, et al. Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. J Dermatolog Treat. 2021;32(8):916–921. doi: 10.1080/09546634.2020.1724250. PubMed DOI

Iversen L, Lange MM, Bissonette R, et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. J Eur Acad Dermatol Venereol. 2017;31(7):1188–1195. doi: 10.1111/jdv.14250. PubMed DOI

Lovato P, Norsgaard H, Tokura Y, Ropke M. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153–164. doi: 10.1016/j.jdermsci.2015.12.009. PubMed DOI

Gniadecki R, Gniadecka M, Serup J. Inhibition of glucocorticoid-induced epidermal and dermal atrophy with KH 1060–a potent 20-epi analogue of 1,25-dihydroxyvitamin D3. Br J Pharmacol. 1994;113(2):439–444. doi: 10.1111/j.1476-5381.1994.tb17008.x. PubMed DOI PMC

Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729. doi: 10.1007/s00403-014-1485-3. PubMed DOI PMC

Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465–471. doi: 10.1684/ejd.2010.0948. PubMed DOI

Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393. doi: 10.1159/000066440. PubMed DOI

Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41. PubMed PMC

Segaert S, Shear NH, Chiricozzi A, et al. Optimizing anti-inflammatory and immunomodulatory effects of corticosteroid and vitamin D analogue fixed-dose combination therapy. Dermatol Ther (Heidelb) 2017;7(3):265–279. doi: 10.1007/s13555-017-0196-z. PubMed DOI PMC

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. doi: 10.1016/j.jaad.2008.12.032. PubMed DOI

Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712. doi: 10.1136/bmj.e6712. PubMed DOI

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(8):931–951. doi: 10.1111/jdv.12058. PubMed DOI

Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432–470. doi: 10.1016/j.jaad.2020.07.087. PubMed DOI

Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. Dermatology. 2021;237(2):166–178. doi: 10.1159/000512930. PubMed DOI

Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14. doi: 10.1111/j.1468-3083.2011.04060.x. PubMed DOI

Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb) 2022;12(10):2217–2231. doi: 10.1007/s13555-022-00794-y. PubMed DOI PMC

Reich A, Selmer J, Galván J, et al. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. Curr Med Res Opin. 2022;38(9):1521–1529. doi: 10.1080/03007995.2022.2078099. PubMed DOI

Bewley A, Barker E, Baker H, et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. J Dermatolog Treat. 2022;33(8):3191–3198. doi: 10.1080/09546634.2022.2116924. PubMed DOI

Armstrong A, Pinter A, Selmer J, Praestegaard M, Reich A, Koo J. Pooled analysis demonstrating superior patient-reported psoriasis treatment outcomes for calcipotriene/betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21(3):242–248. PubMed

Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–425. doi: 10.36849/JDD.5653. PubMed DOI

Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228–236. doi: 10.1111/jdv.17734. PubMed DOI

Feldman SR, Præstegaard M, Andreasen AH, Selmer J, Holm-Larsen T. Validation of the self-reported psoriasis treatment convenience scale (PTCS) Dermatol Ther (Heidelb) 2021;11(6):2077–2088. doi: 10.1007/s13555-021-00626-5. PubMed DOI PMC

Iversen L, Kurvits M, Snel-Prentø AM, Menter A. Calcipotriol/betamethasone dipropionate cutaneous foam treatment for psoriasis in patients with BSA 5–15% and PGA ≥ 3: post-hoc analysis from three randomized controlled trials. Dermatol Ther (Heidelb) 2020;10(5):1111–1120. doi: 10.1007/s13555-020-00419-2. PubMed DOI PMC

Pinter A, Thormann H, Angeletti F, Jalili A. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;11:451–459. doi: 10.2147/CCID.S180698. PubMed DOI PMC

Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18(3):405–411. doi: 10.1007/s40257-017-0258-0. PubMed DOI PMC

Kircik L, Gold LS, Teng J, Moore A, Cantrell W, Alonso-Llamazares JKJ. Fixed combination calcipotriene and betamethasone dipropionate (Cal(BD) foam for beyond-mild psoriasis: a possible alternative to systemic medication. J Drugs Dermatol. 2020;19(8):723. doi: 10.36849/JDD.2020.5300. PubMed DOI

Gerdes S, Krakor M, Anger T, Hutt HJ, Korber A. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233(6):425–434. doi: 10.1159/000486700. PubMed DOI

Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6. doi: 10.1111/j.1468-3083.2005.01329.x. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03308799, NCT03802344